Company intelligence / Profile preview

Tiefenbacher Group

Ownership: Private
Employees: ~800
Development stage: Commercial

Overview

Tiefenbacher Group has a long track record of developing, manufacturing, and registering finished dosage forms—including highly potent drugs—and distributing APIs globally. They have achieved first approvals for new chemical entities and maintain a large portfolio of generic and innovative medicines distributed in over eighty countries. No detailed clinical trial results are published.

Therapeutic areas: OtherNeurology
Modalities: Small moleculeDrug-device combinationMedical device
Industry: Biotech

Partnerships

Not specifically listed; the company licenses out its dossiers/products to marketing partners worldwide and collaborates with API producers and global pharma brands.

Beyond the preview

Go deeper on Tiefenbacher Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiefenbacher Group.

Explore the full profile